Eli Lilly (BATS-CHIXE:LLYZ) - Stock Price, News & Analysis

LLYZ Stock Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

LLYZ fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	1/6
Financial Health	1/6
Dividends	0/6

Rewards

Trading at 20.6% below our estimate of its fair value

Earnings are forecast to grow 27.2% per year

Risk Analysis

Shares are highly illiquid

Debt is not well covered by operating cash flow

High level of non-cash earnings

Eli Lilly and Company Competitors

AstraZeneca

LSE:AZN

UK£185.8b

GSK

LSE:GSK

UK£67.5b

Hikma Pharmaceuticals

LSE:HIK

UK£4.2b

HUTCHMED (China)

AIM:HCM

UK£2.5b

Price History & Performance

Summary of all time highs, changes and price drops for Eli Lilly
Historical stock prices
Current Share Price	US$710.00
52 Week High	US$710.00
52 Week Low	US$388.00
Beta	0.37
1 Month Change	9.23%
3 Month Change	n/a
1 Year Change	107.60%
3 Year Change	n/a
5 Year Change	468.00%
Change since IPO	726.54%

Recent updates

Shareholder Returns

	LLYZ	GB Pharmaceuticals	GB Market
7D	0%	7.8%	2.8%
1Y	107.6%	5.0%	1.1%

Return vs Industry: LLYZ exceeded the UK Pharmaceuticals industry which returned 5% over the past year.

Return vs Market: LLYZ exceeded the UK Market which returned 1.1% over the past year.

Price Volatility

Is LLYZ's price volatile compared to industry and market?
LLYZ volatility
LLYZ Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.0%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: LLYZ has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine LLYZ's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1876	43,000	Dave Ricks	www.lilly.com

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.

Eli Lilly and Company Fundamentals Summary

How do Eli Lilly's earnings and revenue compare to its market cap?
LLYZ fundamental statistics
Market cap	CHF603.79b
Earnings (TTM)	CHF4.79b
Revenue (TTM)	CHF31.18b

126.1x

P/E Ratio

19.4x

P/S Ratio

Is LLYZ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LLYZ income statement (TTM)
Revenue	US$34.12b
Cost of Revenue	US$7.08b
Gross Profit	US$27.04b
Other Expenses	US$21.80b
Earnings	US$5.24b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 30, 2024

Earnings per share (EPS)	5.82
Gross Margin	79.25%
Net Profit Margin	15.36%
Debt/Equity Ratio	233.4%

How did LLYZ perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

78%

Payout Ratio

LLYZ Stock Overview

Rewards

Risk Analysis

Eli Lilly and Company Competitors

LSE:AZN

UK£185.8b

LSE:GSK

UK£67.5b

LSE:HIK

UK£4.2b

AIM:HCM

UK£2.5b

Price History & Performance

Recent News & Updates

Eli Lilly and Company to Report Q1, 2024 Results on Apr 30, 2024

As You Sow Files an Exempt Solicitation Statement and Request Vote for the Proposal

Insufficient new directors

SEIU Benefit Plans Master Trust Files a Notice of Exempt Solicitation to Eli Lilly and Company

Eli Lilly and Company Announces Results from A First-Of-Its-Kind Study of Lebrikizumab

Eli Lilly and Company to Present Donanemab in Early Symptomatic Alzheimer's Disease

Recent updates

Eli Lilly and Company to Report Q1, 2024 Results on Apr 30, 2024

As You Sow Files an Exempt Solicitation Statement and Request Vote for the Proposal

Insufficient new directors

SEIU Benefit Plans Master Trust Files a Notice of Exempt Solicitation to Eli Lilly and Company

Eli Lilly and Company Announces Results from A First-Of-Its-Kind Study of Lebrikizumab

Eli Lilly and Company to Present Donanemab in Early Symptomatic Alzheimer's Disease

Insufficient new directors

Full year 2023 earnings released: EPS: US$5.82 (vs US$6.93 in FY 2022)

Insufficient new directors

Philip Johnson to Retire as Eli Lilly and Company's Treasurer

Upcoming dividend of US$1.30 per share at 0.7% yield

Eli Lilly and Company Provides Earnings Guidance for the Fiscal Year 2024

Insufficient new directors

Third quarter dividend of US$1.30 announced

Johna Norton to Retire as Lilly Executive Vice President of Global Quality

Eli Lilly and Company to Report Q4, 2023 Results on Feb 06, 2024

Eli Lilly and Company Launches End-To-End Digital Healthcare Experience Through LillyDirect

Eli Lilly and Company (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.

Eli Lilly and Company Announces Updated Clinical Data from the International Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Eli Lilly and Company Declares Dividend for the First Quarter of 2024, Payable on March 8, 2024

Eli Lilly and Company Announces Availability of Zepbound (Tirzepatide) Injection

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Jaypirca (Pirtobrutinib) for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphocytic Lymphoma

U.S. Food and Drug Administration Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

Upcoming dividend of US$1.13 per share at 0.8% yield

Third quarter 2023 earnings released: US$0.064 loss per share (vs US$1.61 profit in 3Q 2022)

Eli Lilly and Company Revises Earnings Guidance for the Year 2023

Eli Lilly and Company Announces FDA Approval for Omvoh (Mirikizumab-Mrkz) Infusion (300 mg/15 mL)/Injection (100 mg/mL)

Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer

Eli Lilly and Company to Report Q3, 2023 Results on Nov 02, 2023

Eli Lilly and Company (NYSE:LLY) signed an agreement to acquire Mablink Bioscience S.A.S.

Eli Lilly and Company (NYSE:LLY) signed an agreement to acquire Mablink Bioscience S.A.S.

Eli Lilly and Company Announces Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others for approximately $1.4 billion.

Investor sentiment improves as stock rises 26%

Boehringer Ingelheim and Eli Lilly and Company Announce US FDA Approves Jardiance for Treatment of Adults with Chronic Kidney Disease

Eli Lilly and Company Announces Topline Results from the Libretto-531 Study Evaluating Retevmo

Eli Lilly and Company (NYSE:LLY) acquired Versanis Bio, Inc. from Medicxi Ventures (UK) LLP and others.

Eli Lilly and Company (NYSE:LLY) completed the acquisition of DICE Therapeutics, Inc. (NasdaqGM:DICE) from a group of shareholders.

Second quarter 2023 earnings released: EPS: US$1.95 (vs US$1.06 in 2Q 2022)

Eli Lilly and Company Revises Earnings Guidance for the Full Year 2023

Upcoming dividend of US$1.13 per share at 1.0% yield

Eli Lilly and Company Announces Topline Results from the Libretto-431 Study Evaluating Retevmo

Eli Lilly and Company Announces Results of Two Phase 3 Tirzepatide Studies in Adults with Obesity or Overweight with Weight-Related Comorbidities, Excluding Type 2 Diabetes

Eli Lilly and Company to Report Q2, 2023 Results on Aug 08, 2023

Eli Lilly and Company Presents Full Results from the Phase 3 Trial of Donanemab

Eli Lilly and Company (NYSE:LLY) enter into a definitive agreement to acquire Versanis Bio, Inc. from Medicxi Ventures (UK) LLP and others for approximately $1.925 billion.

Eli Lilly and Company Announces New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Eli Lilly and Company (NYSE:LLY) acquired unknown minority stake in Eli Lilly and Company (NYSE:LLY) from Heidelberg Pharma GmbH.

Eli Lilly and Company Declares Third-Quarter 2023 Dividend, Payable on September 8, 2023

Eli Lilly and Company(NYSE:LLY) dropped from Russell Top 200 Value Index

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire DICE Therapeutics, Inc. (NasdaqGM:DICE) from RA Capital Healthcare Fund, L.P. and RA Capital Healthcare Fund, L.P., funds managed by RA Capital Management, L.P., J. Kevin Judice and others for $2.3 billion.

Eli Lilly and Company Announces First-Of-Its-Kind Head-To-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Attorneys At Hagens Berman and Carella Byrne Cecchi Olstein Brody & Agnello Announces Settlement Worth in Excess of $500 Million Reached in Insulin Pricing Class-Action Lawsuit

Eli Lilly and Company Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis

Upcoming dividend of US$1.13 per share at 1.1% yield

Shareholder Returns

Price Volatility

About the Company